GRAIL, Inc.
10
1
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
Role: lead
PATHFINDER 2: A Multi-Cancer Early Detection Study
Role: lead
Galleri® in the Medicare Population.
Role: lead
REFLECTION: A Clinical Practice Learning Program for Galleri®
Role: lead
Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening
Role: collaborator
The SUMMIT Study: A Cancer Screening Study
Role: collaborator
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
Role: lead
The Galleri® Community Research Program
Role: lead
The Circulating Cell-free Genome Atlas Study
Role: lead
Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
Role: lead
All 10 trials loaded